A phase 3B multicenter, randomized, double-blind, double-dummy comparative trial to evaluate the efficacy and safety of azithromycin SR (microspheres formulation) versus moxifloxacin for the treatment of acute exacerbation of chronic bronchitis (AECB)

Trial Profile

A phase 3B multicenter, randomized, double-blind, double-dummy comparative trial to evaluate the efficacy and safety of azithromycin SR (microspheres formulation) versus moxifloxacin for the treatment of acute exacerbation of chronic bronchitis (AECB)

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2009

At a glance

  • Drugs Azithromycin; Moxifloxacin
  • Indications Acute exacerbations of chronic bronchitis; Bacterial infections; Chronic bronchitis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 17 May 2009 Results have been reported at the 19th European Congress of Clinical Microbiology and Infectious Diseases.
    • 08 Oct 2008 Actual patient number (398) added as reported by ClinicalTrials.gov.
    • 08 Oct 2008 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top